UPDATE : Thursday, August 22, 2019
Lilly anticipates Trulicity’s growth as GLP-1 receptor antagonists get popular by Kim Yun-mi 2019-06-28 16:12
Why people still ask if AIDS is preventable by Kim Yun-mi 2019-06-26 17:02
‘Imbruvica raised survival rate of mantle cell lymphoma patients’ by Kim Yun-mi 2019-06-25 15:34
Latecomer experimental drug no better than Dupixent in trial by Kim Yun-mi 2019-06-24 15:49
Off-label use of Mabthera Inj. denied by Kim Yun-mi 2019-06-20 15:49
‘Korean cancer researchers have risen to world-class level’ by Kim Yun-mi 2019-06-20 15:04
‘Immunotherapies contributed to advancement of neoadjuvant cancer treatment’ by Kim Yun-mi 2019-06-19 15:36
AstraZeneca to invest $630 million in Korean biohealth sector by Kim Yun-mi 2019-06-17 11:33
‘Moon administration to expand investment into healthcare, quality of life’ by Kim Yun-mi 2019-06-14 16:49
Atopic dermatitis patients demand reimbursement for Sanofi’s biological drug by Kim Yun-mi 2019-06-12 13:29
Forxiga prevents kidney disease in diabetes patients by Kim Yun-mi 2019-06-11 15:40
HIV prevention pill to get insurance benefit in Korea by Kim Yun-mi 2019-05-30 13:25
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy by Kim Yun-mi 2019-05-29 12:35
‘Enstilum treats all psoriasis from mild to severe ones’ by Kim Yun-mi 2019-05-28 14:44
‘Risk-sharing agreements back up economic feasibility review’ by Kim Yun-mi 2019-05-22 14:46
Japan issued safety warning on Lilly’s breast cancer drug. Will Korea, too? by Kim Yun-mi 2019-05-21 14:19
Low-income, single women more vulnerable to osteoporosis by Kim Yun-mi 2019-05-20 15:40
Latecomer SGLT2 inhibitor Steglatro unlikely to get free ride by Kim Yun-mi 2019-05-15 15:30
Keytruda wins nod as adjuvant therapy after melanoma surgery by Kim Yun-mi 2019-05-15 14:14
Antibody-drug conjugates on the rise as Herceptin’s patent to expire soon by Kim Yun-mi 2019-05-13 14:23
Back to Top